{
    "clinical_study": {
        "@rank": "4962", 
        "arm_group": [
            {
                "arm_group_label": "Serelaxin dose 1", 
                "arm_group_type": "Experimental", 
                "description": "Patients will receive continuous intravenous infusion of serelaxin for 48 hours at dose 1."
            }, 
            {
                "arm_group_label": "Serelaxin dose 2", 
                "arm_group_type": "Experimental", 
                "description": "Patients will receive continuous intravenous infusion of serelaxin for 48 hours at dose 2."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients will receive continuous intravenous infusion of matching placebo serelaxin for 48 hours."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a multicenter, randomized, double-blind, placebo-controlled study to assess safety,\n      tolerability and pharmacokinetics and to explore efficacy of IV infusion of 10 \u00b5g/kg/day and\n      30 \u00b5g/kg/day serelaxin for 48 hours compared to placebo, when added to the standard therapy,\n      in approximately 45 Japanese AHF patients. This study is intended to support registration of\n      serelaxin for the treatment of AHF in Japan."
        }, 
        "brief_title": "Study of Safety, Tolerability and Pharmacokinetics of Serelaxin in Japanese Acute Heart Failure (AHF) Patients", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Heart Failure", 
        "condition_browse": {
            "mesh_term": "Heart Failure"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written informed consent must be obtained before any study-specific assessment is\n             performed.\n\n          -  Male or female \u226520 years of age, with body weight \u226530 kg and \u2264160 kg\n\n          -  Hospitalized for AHF; AHF is defined as including all of the followings measured at\n             any time between presentation (including the emergency department) and the end of\n             screening:\n\n          -  Dyspnea at rest or with minimal exertion\n\n          -  Pulmonary congestion on chest radiograph\n\n          -  BNP \u2265350 pg/mL or NT-proBNP \u22651,400 pg/mL\n\n          -  SBP \u2265125 mmHg at the start and at the end of screening\n\n          -  Able to be randomized within 16 hours from presentation to the hospital, including\n             the emergency department\n\n          -  Received intravenous (IV) furosemide of at least 40 mg (or equivalent) at any time\n             between presentation (this include outpatient clinic, ambulance, or hospital\n             including emergency department) and the start of screening for the study for the\n             treatment of the current acute heart failure (HF) episode.\n\n          -  Impaired renal function defined as an estimated glomerular filtration rate (eGFR)\n             between presentation and randomization of \u2265 25 and\u2264 75 mL/min/1.73 m2, calculated\n             using the Japanese formula\n\n        Exclusion Criteria:\n\n          -  Dyspnea primarily due to non-cardiac causes\n\n          -  Temperature >38.5\u00b0C (oral or equivalent) or sepsis or active infection requiring IV\n             anti-microbial treatment\n\n          -  Clinical evidence of acute coronary syndrome currently or within 30 days prior to\n             enrollment.\n\n          -  AHF due to significant arrhythmias, which include any of the following: sustained\n             ventricular tachycardia, bradycardia with sustained ventricular rate <45 beats per\n             minute, or atrial fibrillation/flutter with sustained ventricular response of >130\n             beats per minute.\n\n        Other protocol defined inclusion/exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02002702", 
            "org_study_id": "CRLX030A1201"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Serelaxin dose 1", 
                    "Serelaxin dose 2"
                ], 
                "description": "Intravenous infusion", 
                "intervention_name": "Serelaxin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Acute heart failure (AHF),", 
            "Japanese,", 
            "Safety and tolerability, Pharmacokinetics,", 
            "Renal Impairment"
        ], 
        "lastchanged_date": "January 29, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Seto-city", 
                        "country": "Japan", 
                        "state": "Aichi", 
                        "zip": "489-8642"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fukuoka-city", 
                        "country": "Japan", 
                        "state": "Fukuoka", 
                        "zip": "810-0001"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Iizuka", 
                        "country": "Japan", 
                        "state": "Fukuoka", 
                        "zip": "820-8505"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hiroshima-city", 
                        "country": "Japan", 
                        "state": "Hiroshima", 
                        "zip": "730-8518"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amagasaki-city", 
                        "country": "Japan", 
                        "state": "Hyogo", 
                        "zip": "660-0828"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Higashiibaraki-gun", 
                        "country": "Japan", 
                        "state": "Ibaraki", 
                        "zip": "311-3193"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kanazawa", 
                        "country": "Japan", 
                        "state": "Ishikawa", 
                        "zip": "920-8650"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kawasaki-city", 
                        "country": "Japan", 
                        "state": "Kanagawa", 
                        "zip": "211-8533"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yokohama-city", 
                        "country": "Japan", 
                        "state": "Kanagawa", 
                        "zip": "231-8682"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sendai-city", 
                        "country": "Japan", 
                        "state": "Miyagi", 
                        "zip": "981-3107"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ueda-city", 
                        "country": "Japan", 
                        "state": "Nagano", 
                        "zip": "386-8610"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Osaka-city", 
                        "country": "Japan", 
                        "state": "Osaka", 
                        "zip": "534-0021"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sayama-city", 
                        "country": "Japan", 
                        "state": "Saitama", 
                        "zip": "350-1323"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Komatsushima-city", 
                        "country": "Japan", 
                        "state": "Tokushima", 
                        "zip": "773-8502"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Itabashi-ku", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "173-8610"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Assess the Safety, Tolerability and Pharmacokinetics of Serelaxin When Added to Standard Therapy in Japanese Acute Heart Failure Patients", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "+81337978748"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Adverse events will be assessed through day 5 and serious adverse events through day 14.", 
                "measure": "Number of patients with total adverse events, serious adverse events and death", 
                "safety_issue": "Yes", 
                "time_frame": "From baseline to Day 14"
            }, 
            {
                "description": "Blood will be collected.", 
                "measure": "Pharmacokinetics of serelaxin: steady-state concentration (Css)", 
                "safety_issue": "No", 
                "time_frame": "From baseline to 56 hours"
            }, 
            {
                "description": "Blood will be collected.", 
                "measure": "Pharmacokinetics of serelaxin: rate of clearance (CL)", 
                "safety_issue": "No", 
                "time_frame": "From baseline to 56 hours"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02002702"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Blood pressure measurements will be done for 30 & 60 minutes and then every hour for the first 6 hours of study drug infusion, and then every 3 hours during study drug infusion, including night time hours. Post-infusion, blood pressure are to be measured every 3 hours until 12 hours following end of infusion, then every 6 hours for 48 hours and then every 24 hours until the earlier of Day 5.", 
                "measure": "Area under the curve (AUC) for changes in systolic blood pressure (SBP) through 48 hours of infusion and through Day 5", 
                "safety_issue": "No", 
                "time_frame": "From baseline to through 48 hours of infusion and through Day 5"
            }, 
            {
                "description": "Change from baseline in cardio-renal biomarkers will be summarized by treatment.", 
                "measure": "Change from baseline in cardio-renal biomarkers through Day 14", 
                "safety_issue": "No", 
                "time_frame": "From baseline to Day 14"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}